Zynerba Pharmaceuticals (ZYNE) Files $57.5M Common Stock IPO

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) filed a registration for an IPO of its Common Stock. The proposed maximum offering price is $57.5 million. The company plans to list on the Nasdaq under the ticker, "ZYNE."

Underwriters are Jefferies, Piper Jaffray, Canaccord Genuity, and Oppenheimer & Co.

Zynerba Pharma is a ten-year-old specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. The company said, Our management team is highly experienced and has a successful history of development, regulatory approval and commercialization of patch and gel transdermal delivery products. We are evaluating two patent-protected product candidates, ZYN002 and ZYN001, in five indications. We intend to study ZYN002 in patients with refractory epilepsy, Fragile X syndrome, or FXS, and osteoarthritis, or OA. We intend to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain. We expect to initiate Phase 1 clinical trials for ZYN002 in the second half of 2015 and ZYN001 by mid-2016.

You May Also Be Interested In

• Gores Holdings XI closes $358.8M IPO on Nasdaq
• Gores Holdings XI prices $312M IPO on Nasdaq
• Neucleus Group files for IPO on Nasdaq at $4-$5 per share